Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases

European Journal of Cardio-thoracic Surgery

Volumn 38, Issue 5, 2010, Pages 621-627

  Den Hengst, Willem A ^a   Van Putte, Bart P ^b   Hendriks, Jeroen M H ^a   Stockman, Bernard ^a   van Boven, Wim Jan P ^b   Weyler, Joost ^c   Schramel, Franz M N H ^b   Van Schil, Paul E Y ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Isolated lung perfusion; Lung function; Melphalan; Prognosis; Pulmonary metastases; Pulmonary toxicity

Indexed keywords

MELPHALAN;

ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HYDROTHORAX; ISOLATED LUNG; KIDNEY CANCER; LUNG FUNCTION; LUNG METASTASIS; LUNG PERFUSION; LUNG SARCOMA; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOGRAPHY; RECURRENT DISEASE; SALIVARY GLAND; SARCOMA; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; EPIDEMIOLOGIC METHODS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REOPERATION; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

EID: 77957893917     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.03.048     Document Type: Article

References (25)

1. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37-49.
2. Smith R., Pak Y., Kraybill W., Kane J.M. Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. Eur J Surg Oncol 2009, 35:356-361.
3. Chen F., Miyahara R., Bando T., Okubo K., Watanabe K., Nakayama T., Toguchida J., Date H. Prognostic factors of pulmonary metastasectomy for osteosarcomas of the extremities. Eur J Cardiothorac Surg 2008, 34:1235-1239.
4. Chen F., Fujinaga T., Sato K., Sonobe M., Shoji T., Sakai H., Miyahara R., Bando T., Okubo K., Hirata T., Date H. Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma. Eur J Surg Oncol 2009, 35:660-665.
5. Lee W.S., Yun S.H., Chun H.K., Lee W.Y., Yun H.R., Kim J., Kim K., Shim Y.M. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007, 22:699-704.
6. Joosten J., Bertholet J., Keemers-Gels M., Barendregt W., Ruers T. Pulmonary resection of colorectal metastases in patients with or without a history of hepatic metastases. Eur J Surg Oncol 2008, 34:895-899.
7. Welter S., Jacobs J., Krbek T., Krebs B., Stamatis G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg 2007, 84:203-210.
8. Watanabe K., Nagai K., Kobayashi A., Sugito M., Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg 2009, 96:1058-1065.
9. Van Schil P.E., Hendriks J.M., van Putte B.P., Stockman B.A., Lauwers P.R., Ten Broecke P.W., Grootenboers M.J., Schramel F.M. Isolated lung perfusion and related techniques for the treatment of pulmonary metastases. Eur J Cardiothorac Surg 2008, 33:487-496.
10. Hendriks J.M., Grootenboers M.J., Schramel F.M., van Boven W.J., Stockman B., Seldenrijk C.A., ten B.P., Knibbe C.A., Slee P., De B.E., Vlaeminck R., Heeren J., Vermorken J.B., van P.B., Romijn S., Van M.E., Van Schil P.E. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial. Ann Thorac Surg 2004, 78:1919-1926.
11. Grootenboers M.J., Schramel F.M., van Boven W.J., van Putte B.P., Hendriks J.M., Van Schil P.E. Re-evaluation of toxicity and long-term follow-up of isolated lung perfusion with melphalan in patients with resectable pulmonary metastases: a phase I and extension trial. Ann Thorac Surg 2007, 83:1235-1236.
12. Johnston M.R., Minchen R.F., Dawson C.A. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 1995, 110:368-373.
13. Ratto G.B., Toma S., Civalleri D., Passerone G.C., Esposito M., Zaccheo D., Canepa M., Romano P., Palumbo R., De C.F., Scarano F., Vannozzi M., Spessa E., Fantino G. Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1996, 112:614-622.
14. Minchin R.F., Johnston M.R., Aiken M.A., Boyd M.R. Pharmacokinetics of doxorubicin in isolated lung of dogs and humans perfused in vivo. J Pharmacol Exp Ther 1984, 229:193-198.
15. Pass H.I., Mew D.J., Kranda K.C., Temeck B.K., Donington J.S., Rosenberg S.A. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg 1996, 61:1609-1617.
16. Burt M.E., Liu D., Abolhoda A., Ross H.M., Kaneda Y., Jara E., Casper E.S., Ginsberg R.J., Brennan M.F. Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial. Ann Thorac Surg 2000, 69:1542-1549.
17. Schroder C., Fisher S., Pieck A.C., Muller A., Jaehde U., Kirchner H., Haverich A., Macchiarini P. Technique and results of hyperthermic (41 degrees C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis. Eur J Cardiothorac Surg 2002, 22:41-46.
18. Hendriks J.M., Van Schil P.E., De B.G., Lauwers P.R., Van Oosterom A.A., Van Marck E.A., Eyskens E.J. Isolated lung perfusion with melphalan and tumor necrosis factor for metastatic pulmonary adenocarcinoma. Ann Thorac Surg 1998, 66:1719-1725.
19. Hendriks J.M., Van Schil P.E., Van Oosterom A.A., Kuppen P.J., Van M.E., Eyskens E. Isolated lung perfusion with melphalan prolongs survival in a rat model of metastatic pulmonary adenocarcinoma. Eur Surg Res 1999, 31:267-271.
20. Grootenboers M.J., Hendriks J.M., van Boven W.J., Knibbe C.A., van P.B., Stockman B., De B.E., Vermorken J.B., Van Schil P.E., Schramel F.M. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial. J Surg Oncol 2007, 96:583-589.
21. Murthy S.C., Kim K., Rice T.W., Rajeswaran J., Bukowski R., DeCamp M.M., Blackstone E.H. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?. Ann Thorac Surg 2005, 79:996-1003.
22. Assouad J., Petkova B., Berna P., Dujon A., Foucault C., Riquet M. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 2007, 84:1114-1120.
23. Piltz S., Meimarakis G., Wichmann M.W., Hatz R., Schildberg F.W., Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002, 73:1082-1087.
24. Lin B.R., Chang T.C., Lee Y.C., Lee P.H., Chang K.J., Liang J.T. Pulmonary resection for colorectal cancer metastases: duration between cancer onset and lung metastasis as an important prognostic factor. Ann Surg Oncol 2009, 16:1026-1032.
25. Carballo M., Maish M.S., Jaroszewski D.E., Holmes C.E. Video-assisted thoracic surgery (VATS) as a safe alternative for the resection of pulmonary metastases: a retrospective cohort study. J Cardiothorac Surg 2009, 4:13.